Pomerantz LLP Alerts Shareholders to Investor Suit Involving aTyr Pharma, Inc. – ATYR

NEW YORK CITY, NY / ACCESS Newswire / November 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ:ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are […]

MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / November 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ:MLTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

From The Brand That Does Baby Luxury Best, Nuna Unveils Its Exclusive Wardrobe Collection

Nuna, a globally-recognized leader in premium baby gear innovation, is thrilled to unveil Nuna Wardrobe-an exclusive line of elevated closet essentials and heirloom-worthygiftables crafted from the finest Mongolian Cashmereand buttery-softSupima® cotton. https://mma.prnewswire.com/media/2816091/Nuna_Baby___Nuna_Wardrobe.jpg Nuna Wardrobereflects the same meticulous care and forward-thinking approach that sets its baby gear apart, blending modern minimalism with intentional comfort, and features

Calumet Reports Third Quarter 2025 Results

— Third quarter 2025 net income of $313.4 million, or basic income per common share of $3.61 — Third quarter 2025 Adjusted EBITDA with Tax Attributes of $92.5 million — Company-wide cost reduction initiatives driving $61 million of year-over-year operating cost savings through the first nine months of 2025 — Montana Renewables remains on track

Brookfield Infrastructure Reports Strong Third Quarter 2025 Results

(NYSE:BIP),(TSX:BIP.UN),(TSX:BIP-UN),(NYSE:BIPC),(TSX:BIPC), BROOKFIELD, News, Nov. 07, 2025 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners L.P. (Brookfield Infrastructure, BIP, or the Partnership) (NYSE: BIP; TSX: BIP.UN) today announced its results for the third quarter ended September 30, 2025. “Brookfield Infrastructure delivered another solid quarter, generating strong financial results and achieving our annual growth and asset sale objectives,” said

K-Tech Rings the Closing Bell on the Nasdaq

(NASDAQ:KMRK), Hong Kong, Nov. 07, 2025 (GLOBE NEWSWIRE) — K-Tech Solutions Company Limited, an innovator in the design and development of educational toy products, proudly announces that on October 2, 2025 they rang the closing bell on Nasdaq Stock Market (“Nasdaq”) in New York to commemorate the successful completion of its recent public listing. The

Mobilicom Secures Follow-On Production Order from Asia-Based Tier-1 Robotics Manufacturer Bringing Cumulative Orders to $315,000

(NASDAQ:MOB),(NASDAQ:MOBBW),(AUST:MOB.AX), More production orders expected, reinforcing Mobilicom's expanding geographic reach and growing traction in the robotics sector Palo Alto, California, Nov. 07, 2025 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced it has received a follow-on production order

Evergold Announces Closing of $350,000 Convertible Debenture Private Placement with CJ “Charlie” Greig; Drilling at DEM is Underway

(TSX-V:EVER),(OTC US:EVGUF),(Other OTC:EVGUF),(Frankfurt:5EG), TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Evergold Corp. (TSX-V: EVER, WKN: A2PTHZ) (“Evergold” or the “Company“) is pleased to announce that it has closed its non-brokered private placement of an unsecured convertible debenture (the “Convertible Debenture“) for aggregate gross proceeds of $350,000 (“Offering“). The Convertible Debenture bears interest at a rate

GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related discontinuations Dose dependent increases in immunocytokines and vector persistence in peripheral blood mononuclear cells at the two highest dose levels support GEN2 transgene expression and mechanism of

Inspired Announces Closing of Sale of UK Holiday Parks Business to Genda Inc.

(NASDAQ:INSE), NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware, and services, today announced the completion of the previously announced sale of its UK holiday parks business and certain associated leisure assets to GENDA Inc. (“GENDA,” TSE:9166), a global entertainment company,

Scroll to Top